Avoplacel is a Cell Therapy owned by Pluri, and is involved in 5 clinical trials, of which 3 were completed, and 2 are planned.
PLXR-18 cells acts as mitigators of the acute radiation syndrome (ARS) by alleviating radiation damages. PLX cells are cytoprotective, which play an important role in protecting bone marrow cells from the adverse effects of radiation exposure. PLX-R18 cells act via integrated secretion of many specific therapeutic proteins in response to chemical signals from a damaged hematopoietic system, and that over time these proteins stimulate the recovery of the bone marrow’s microenvironment. They also acts by renewal and differentiation of those progenitor cells that produce the body’s red cells, white cells, platelets and also by migration of those cells into the blood stream to function.
The revenue for Avoplacel is expected to reach a total of $25m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Avoplacel NPV Report.
Avoplacel is originated and owned by Pluri.
Avoplacel (PLXR-18) is under development for the treatment of acute radiation syndrome and incomplete hematopoietic recovery following bone marrow transplantation. The therapeutic candidate is an allogeneic product. The therapeutic candidate is administered through intramuscular route. It is developed based on a three-dimensional technology platform which enables the conversion of human placental cells into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues.
It was also under development for the treatment of chemotherapy induced bone marrow hypoplasia, and aplastic anemia.
Pluri, formerly Pluristem Therapeutics is a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. The company’s placental expanded cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. Pluri’s product pipeline includes PLX-PAD for critical limb ischemia, intermittent claudication, orthopedic conditions, pulmonary arterial hypertension and women’s health. The company’s PLX-Immune for kidney, colorectal, breast, lung, muscle, skin and liver cancers, PLX-R18 for hematological system and acute radiation syndrome. Pluri harnesses its proprietary 3D cell expansion platform technology for developing its cell therapies. It works in partnership with medical, pharmaceutical and academic institutions. Pluri is headquartered in Haifa, Israel.
The company reported revenues of (US Dollars) US$0.2 million for the fiscal year ended June 2022 (FY2022). The operating loss of the company was US$41.6 million in FY2022, compared to an operating loss of US$50.6 million in FY2021. The net loss of the company was US$41.4 million in FY2022, compared to a net loss of US$49.9 million in FY2021.
Quick View – Avoplacel
|Highest Development Stage|